Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon
Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon
复制标题
DOI：
10.1128/jvi.00815-06
复制
发表时间：
2007-01-01
影响因子：
5.4
通讯作者：
Sparger, Ellen E.
中科院分区：
文献类型：
--
作者：
Gupta, Soumi;Leutenegger, Christian M.;Sparger, Ellen E.
将共表达猫γ干扰素（IFN-γ）的具有vif基因缺失的猫免疫缺陷病毒（FIV）前病毒（FIV Delta vifATG γ）作为前病毒DNA疫苗进行测试，以扩展先前显示FIV-pPPR Delta vif DNA疫苗的功效的研究。用FIV Delta vifATG γ或FIV-pPPR Delta vif前病毒质粒DNA或FIV-pPPR Delta vif DNA和猫IFN-γ表达质粒（pCDNA-IFN γ）两者接种猫。在用FIV Delta vifATG γ或FIV-pPPR Delta vif加pCDNA-IFN γ免疫的猫中观察到更高频率的FIV特异性T细胞增殖应答，而疫苗组之间的病毒特异性细胞毒性T淋巴细胞应答相当。接种后未观察到抗病毒抗体。免疫后13周，用生物FIV分离株（FIV-PPR）攻毒后，疫苗组之间的病毒特异性细胞和免疫应答相似。所有接种疫苗和未接种疫苗的猫在FIV-PPR攻毒后均被感染，并表现出相似的血浆病毒载量。因此，包含含有IFN-γ的质粒不会增强FIV-pPPR Delta vif DNA免疫的功效。有趣的是，缺乏与FIV-pPPR Delta vif DNA免疫相关的保护与先前研究的结果形成对比，并表明多种因素，包括FIV-pPPR Delta vif接种和攻击的时机，以及攻击病毒递送的途径，可能会显著影响疫苗效力。
A feline immunodeficiency virus (FIV) provirus with a vif gene deletion (FIV Delta vifATG gamma) that coexpresses feline gamma interferon (IFN-gamma) was tested as a proviral DNA vaccine to extend previous studies showing efficacy with an FIV-pPPR Delta vif DNA vaccine. Cats were vaccinated with either FIV Delta vifATG gamma or FIV-pPPR Delta vif proviral plasmid DNA or with both FIV-pPPR Delta vif DNA and a feline IFN-gamma expression plasmid (pCDNA-IFN gamma). A higher frequency of FIV-specific T-cell proliferation responses was observed in cats immunized with either FIV Delta vifATG gamma or FIV-pPPR Delta vif plus pCDNA-IFN gamma, while virus-specific cytotoxic-T-lymphocyte responses were comparable between vaccine groups. Antiviral antibodies were not observed postvaccination. Virus-specific cellular and Immoral responses were similar between vaccine groups after challenge with a biological FIV isolate (FIV-PPR) at 13 weeks postimmunization. All vaccinated and unvaccinated cats were infected after FIV-PPR challenge and exhibited similar plasma virus loads. Accordingly, inclusion of plasmids containing IFN-gamma did not enhance the efficacy of FIV-pPPR Delta vif DNA immunization. Interestingly, the lack of protection associated with FIV-pPPR Delta vif DNA immunization contrasted with findings from a previous study and suggested that multiple factors, including timing of FiV-pPPR Delta vif inoculations and challenge, as well as route of challenge virus delivery, may significantly impact vaccine efficacy.